These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 18598765

  • 1. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
    Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C.
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
    [Abstract] [Full Text] [Related]

  • 2. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Sep; 16(5):897-906. PubMed ID: 19436226
    [Abstract] [Full Text] [Related]

  • 3. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

  • 4. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 5. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 May; 16(5):923-31. PubMed ID: 19424093
    [Abstract] [Full Text] [Related]

  • 6. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 May; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 7. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 8. A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.
    Labrie F, Martel C.
    Horm Mol Biol Clin Investig; 2017 Feb 01; 29(2):39-60. PubMed ID: 27997350
    [Abstract] [Full Text] [Related]

  • 9. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women.
    Labrie F, Bélanger A, Labrie C, Candas B, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2007 Oct 01; 107(1-2):57-69. PubMed ID: 17627814
    [Abstract] [Full Text] [Related]

  • 10. Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat.
    Berger L, El-Alfy M, Labrie F.
    J Steroid Biochem Mol Biol; 2008 Mar 01; 109(1-2):67-80. PubMed ID: 18242978
    [Abstract] [Full Text] [Related]

  • 11. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
    Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R, other participating members of VVA Prasterone Group.
    Menopause; 2015 Dec 01; 22(12):1289-95. PubMed ID: 25968836
    [Abstract] [Full Text] [Related]

  • 12. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M, Monteleone P, Casarosa E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2000 Oct 01; 14(5):342-63. PubMed ID: 11109974
    [Abstract] [Full Text] [Related]

  • 13. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
    Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B.
    J Clin Endocrinol Metab; 1997 Oct 01; 82(10):3498-505. PubMed ID: 9329392
    [Abstract] [Full Text] [Related]

  • 14. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec 01; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 15. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).
    Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, Sood R, Griffin P, Terstriep SA, Mattar B, Lafky JM, Loprinzi CL.
    Support Care Cancer; 2018 Apr 01; 26(4):1335-1343. PubMed ID: 29164377
    [Abstract] [Full Text] [Related]

  • 16. Metabolism of DHEA in postmenopausal women following percutaneous administration.
    Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Chaussade V, Castiel I, Deloche C, Leclaire J.
    J Steroid Biochem Mol Biol; 2007 Feb 01; 103(2):178-88. PubMed ID: 17084625
    [Abstract] [Full Text] [Related]

  • 17. Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA.
    Ke Y, Gonthier R, Simard JN, Archer D, Lavoie L, Martel C, Vaillancourt M, Labrie F.
    Horm Mol Biol Clin Investig; 2015 Dec 01; 24(3):117-29. PubMed ID: 26509785
    [Abstract] [Full Text] [Related]

  • 18. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J.
    Gynecol Endocrinol; 2010 Jul 01; 26(7):524-32. PubMed ID: 20459349
    [Abstract] [Full Text] [Related]

  • 19. Science of intracrinology in postmenopausal women.
    Labrie F, Bélanger A, Pelletier G, Martel C, Archer DF, Utian WH.
    Menopause; 2017 Jun 01; 24(6):702-712. PubMed ID: 28098598
    [Abstract] [Full Text] [Related]

  • 20. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF.
    J Steroid Biochem Mol Biol; 2015 Jan 01; 145():139-43. PubMed ID: 25201455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.